Duloxetine Capsule, Delayed Release
Product Images NDC 80425-0311

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 80425-0311). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label 1 (Duloxetine Dr 20mg 80425 0311 01)

Packaging label for Duloxetine DR 20 mg delayed-release oral capsules by Advanced Rx Pharmacy of Tennessee. The label includes dosing information, a comparison to Cymbalta with associated NDC numbers, lot number, and expiration date 10/31/2024. It is packaged as a bottle containing 30 capsules.*

FDA Label Image

Label 2 (Duloxetine Dr 20mg 80425 0311 02)

Duloxetine DR 20 mg delayed-release capsules packaging label from Advanced Rx Pharmacy of Tennessee, LLC, Nashville, TN. The label includes storage instructions (20°C-25°C), comparison to Cymbalta, quantity (#60), and lot/expiration information. The product NDC is 80425-0311.*

FDA Label Image

Label 3 (Duloxetine Dr 20mg 80425 0311 03)

Duloxetine DR 20 mg delayed release capsule label from Advanced Rx Pharmacy of Tennessee, LLC. The label includes storage instructions (20-25°C), comparison to Cymbalta, the National Drug Code (NDC 80425-0311-03), and an expiration date of 10/31/2024. Ajanta Pharma L. is noted as the manufacturer.*

FDA Label Image

Figure 10 (Image 11)

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily versus placebo. The y-axis shows the percentage of patients improved, and the x-axis shows percent improvement in pain. Two trend lines display patient improvement outcomes for each group.*

FDA Label Image

Figure 1 (Image 2)

A Kaplan-Meier survival curve chart showing the proportion of patients with relapse over time in days from randomization. Two lines compare the treatment groups: placebo (dashed line) and Duloxetine (solid line), illustrating lower relapse proportions over time with Duloxetine.*

FDA Label Image

Figure 3 (Image 4)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, with percentage improvements on the x-axis and percentage of patients improved on the y-axis. The data illustrate patient response differences across these treatment groups.*

FDA Label Image

Figure 4 (Image 6)

A line graph showing the percentage of patients improved against the percent improvement in pain from baseline. Three data series compare Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, illustrating patient response rates at various levels of pain improvement.*

FDA Label Image

Structure (Image 7)

A line graph illustrating the percentage of patients improved based on percent improvement in pain from baseline. The graph compares Duloxetine 60mg taken twice daily, Duloxetine 60mg taken once daily, and a placebo group, showing trends in patient improvement across varying pain improvement percentages from 0% to 100%.*

FDA Label Image

Figure 6 (Image 8)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at 20 mg, 60 mg, and 120 mg doses compared to placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved. Duloxetine lines show a higher percentage of patients improved compared to placebo across the range.*

FDA Label Image

Figure 8 (Image 9)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis shows increasing percent improvement thresholds from >0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100. The Duloxetine group shows consistently higher percentages of patients improved across the pain improvement thresholds compared to placebo.*

FDA Label Image

Structure (Image)

Chemical structure of duloxetine hydrochloride, showing the molecular arrangement of duloxetine with its naphthalene, thiophene, and amine groups.*

FDA Label Image

Figure 9 (Image10)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from baseline, ranging from greater than 0 to 100%, while the y-axis shows the percentage of patients improved, ranging from 0 to 100%. Two lines track patient improvement, with Duloxetine showing consistently higher improvement percentages compared to placebo.*

FDA Label Image

Structure (Image3)

A Kaplan-Meier curve graph displaying the proportion of patients with relapse over time in days from randomization. The graph compares two treatments: Placebo (dashed line) and Duloxetine (solid line), showing a lower proportion of relapse in the Duloxetine group throughout the observed period up to 250 days.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.